Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
J Nucl Med
; 59(3): 452-458, 2018 03.
Article
in En
| MEDLINE
| ID: mdl-28775205
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Organometallic Compounds
/
Pancreatic Neoplasms
/
Stomach Neoplasms
/
Octreotide
/
Receptors, Peptide
/
Neuroendocrine Tumors
/
Intestinal Neoplasms
Type of study:
Etiology_studies
/
Incidence_studies
/
Prognostic_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Nucl Med
Year:
2018
Document type:
Article
Affiliation country:
Netherlands